# A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Source: https://onco.cc/trials/nct06609005/  
OnCo record `nct06609005` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of INV-9956 in prostate cancer, run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.

## Summary

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT06609005 by Shenzhen Ionova Life Sciences Co., Ltd., with 84 participants planned, started 2025-01-23 and due to reach its primary completion in 2028-01-17. Interventions recorded: INV-9956.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06609005
- Phase: 1/2
- Setting: A Phase 1 and Phase 2, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
- Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT06609005: https://clinicaltrials.gov/study/NCT06609005

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06609005.json